Why the study?
Does ticagrelor monotherapy reduce mortality and clinical adverse events in post-PCI acute coronary syndrome (ACS) patients?
Does ticagrelor monotherapy reduce mortality and clinical adverse events in post-PCI acute coronary syndrome (ACS) patients?
Ticagrelor monotherapy following a brief period of DAPT is a balanced strategy for managing bleeding and ischemic risks in high-risk post-PCI ACS patients.
Answers are grounded in this paper and cite their sources.
Supports transitioning to early ticagrelor monotherapy to balance bleeding and ischemic risks.
-analyses validate ticagrelor monotherapy's role in lowering mortality and clinical adverse events versus conventional DAPT. The review endorses a personalized treatment regimen, beginning with DAPT before moving to ticagrelor monotherapy, as a balanced method for managing both bleeding and ischemic risks in post-PCI acute coronary syndrome (ACS) patients, especially those facing higher bleeding threats.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: